+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis



A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis



Journal of Cystic Fibrosis 10(5): 343-349



Aerosol delivery is a cornerstone of CF airways disease management. New nebulisers have reduced treatment times by utilising mesh technology for aerosol production. We have evaluated a further modification (target inhalation mode (TIM)) that may reduce treatment delivery times further. Following a baseline period on tidal breathing mode (TBM), children with CF on long-term aerosol therapy were randomly allocated to either TIM, which optimises patient inhalations through a direct feedback mechanism, or to continue TBM. The primary outcome was nebuliser treatment times with secondary outcomes being adherence and patient preference. The ten children allocated TIM reduced their mean (SD) treatment times from 6.9(2.9) to 3.7(2.3) minutes (p<0.001). In contrast, treatment times were unchanged in the ten children allocated TBM. Mean adherence was maintained in the TIM group but declined in patients allocated TBM by >5%. All children preferred TIM to TBM. TIM reduces nebuliser treatment times and may positively impact on adherence, although longer duration studies are required to examine this. (ISRCTN65617839).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036105369

Download citation: RISBibTeXText

PMID: 21620782

DOI: 10.1016/j.jcf.2011.04.006


Related references

Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. Journal of Cystic Fibrosis 8(4): 258-263, 2009

Exercise with incorporated expiratory manoeuvres was as effective as breathing techniques for airway clearance in children with cystic fibrosis: a randomised crossover trial. Journal of PhysioTherapy 58(4): 241-247, 2013

Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 29(3): 242-250, 2017

Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial. Lancet (North American Edition) 360(9338): 978-984, September 28, 2002

Oral Protein Energy Supplements for Children With Cystic Fibrosis: CALICO Multicentre Randomised Controlled Trial. Yearbook of Pediatrics 2007: 149-150, 2007

Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ 332(7542): 632-636, 2006

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125(2): 509-521, 2004

CyFiT telehealth: protocol for a randomised controlled trial of an online outpatient physiotherapy service for children with cystic fibrosis. Bmc Pulmonary Medicine 19(1): 21-21, 2019

Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis 17(3): 375-382, 2017

Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial. Respiratory Medicine 148: 24-30, 2019

Benefits of combining inspiratory muscle with 'whole muscle' training in children with cystic fibrosis: a randomised controlled trial. British Journal of Sports Medicine 48(20): 1513-1517, 2015

Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 69(12): 1073-1079, 2015

Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax 35(1): 42-46, 1980

Controlled trial of intermittent aerosol therapy with sodium 2 mercapto ethanesulfonate in cystic fibrosis. Thorax 35(1): 42-46, 1980

Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Yearbook of Medicine 2009: 332-333, 2009